Rhett P Ketterling

List of Publications by Citations

Source: https://exaly.com/author-pdf/708003/rhett-p-ketterling-publications-by-citations.pdf
Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

462 papers	14,515 citations	57 h-index	110 g-index
465 ext. papers	16,985 ext. citations	4.5 avg, IF	6 L-index

#	Paper	IF	Citations
462	Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. *New England Journal of Medicine*, **2012**, 366, 1079-89	59.2	1378
461	Anthracycline dose intensification in acute myeloid leukemia. *New England Journal of Medicine*, **2009**, 361, 1249-59	59.2	658
460	Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. *Blood*, **2014**, 124, 2507-13; quiz 2615	2.2	424
459	CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. *Blood*, **2003**, 102, 3093-6	2.2	327
458	Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases. *Blood*, **2005**, 105, 973-7	2.2	305
457	Microduplication 22q11.2, an emerging syndrome: clinical, cytogenetic, and molecular analysis of thirteen patients. *American Journal of Human Genetics*, **2003**, 73, 1027-40	11	298
456	ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes. *Blood*, **2014**, 124, 1473-80	2.2	294
455	T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993). *Blood*, **2009**, 114, 5136-45	2.2	277
454	FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia. *Blood*, **2004**, 104, 3038-45	2.2	248
453	MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis. *Journal of Clinical Oncology*, **2018**, 36, 310-318	2.2	224
452	Lenalidomide therapy in myelofibrosis with myeloid metaplasia. *Blood*, **2006**, 108, 1158-64	2.2	211
451	Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905. *Journal of Clinical Oncology*, **2014**, 32, 1242-8	2.2	187
450	ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients. *Leukemia*, **2014**, 28, 2206-12	10.7	186
449	Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics. *Blood*, **2012**, 119, 2100-5	2.2	181
448	HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial. *Journal of Clinical Oncology*, **2010**, 28, 4307-15	2.2	175
447	SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value. *Blood*, **2012**, 119, 569-72	2.2	164
446	Genome-wide analysis reveals recurrent structural abnormalities of TP63 and other p53-related genes in peripheral T-cell lymphomas. *Blood*, **2012**, 120, 2280-9	2.2	164

445	Targeted deep sequencing in polycythemia vera and essential thrombocythemia. *Blood Advances*, **2016**, 1, 21-30	7.8	163
444	Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999. *Blood*, **2010**, 116, 4077-85	2.2	157
443	Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes. *Leukemia*, **2013**, 27, 1504-10	10.7	151
442	Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: a collaborative study of 1027 patients. *American Journal of Hematology*, **2014**, 89, E121-4	7.1	145
441	Factor VIII gene inversions causing severe hemophilia A originate almost exclusively in male germ cells. *Human Molecular Genetics*, **1994**, 3, 1035-9	5.6	144
440	One thousand patients with primary myelofibrosis: the mayo clinic experience. *Mayo Clinic Proceedings*, **2012**, 87, 25-33	6.4	137
439	Clonally related histiocytic/dendritic cell sarcoma and chronic lymphocytic leukemia/small lymphocytic lymphoma: a study of seven cases. *Modern Pathology*, **2011**, 24, 1421-32	9.8	135
438	Clinical correlates of JAK2V617F allele burden in essential thrombocythemia. *Cancer*, **2007**, 109, 2279-84	6.4	132
437	SRSF2 mutations in primary myelofibrosis: significant clustering with IDH mutations and independent association with inferior overall and leukemia-free survival. *Blood*, **2012**, 120, 4168-71	2.2	128
436	Chromosomal rearrangements of 6p25.3 define a new subtype of lymphomatoid papulosis. *American Journal of Surgical Pathology*, **2013**, 37, 1173-81	6.7	125
435	Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS. *Blood*, **2012**, 120, 1290-8	2.2	123
434	Targeted deep sequencing in primary myelofibrosis. *Blood Advances*, **2016**, 1, 105-111	7.8	120
433	GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis. *Leukemia*, **2018**, 32, 1631-1642	10.7	117
432	Spliceosome mutations involving SRSF2, SF3B1, and U2AF35 in chronic myelomonocytic leukemia: prevalence, clinical correlates, and prognostic relevance. *American Journal of Hematology*, **2013**, 88, 201-6	7.1	112
431	Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: a Mayo Clinic study of 277 patients. *Leukemia*, **2012**, 26, 101-5	10.7	112
430	FIP1L1-PDGFRA in eosinophilic disorders: prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature. *Leukemia Research*, **2006**, 30, 965-70	2.7	110
429	The prognostic advantage of calreticulin mutations in myelofibrosis might be confined to type 1 or type 1-like CALR variants. *Blood*, **2014**, 124, 2465-6	2.2	105
428	Molecular and prognostic correlates of cytogenetic abnormalities in chronic myelomonocytic leukemia: a Mayo Clinic-French Consortium Study. *American Journal of Hematology*, **2014**, 89, 1111-5	7.1	104

427	Relationship of patient survival and chromosome anomalies detected in metaphase and/or interphase cells at diagnosis of myeloma. *Blood*, **2005**, 106, 3553-8	2.2	100
426	Prognostic interaction between ASXL1 and TET2 mutations in chronic myelomonocytic leukemia. *Blood Cancer Journal*, **2016**, 6, e385	7	83
425	Utility of ALK-1 protein expression and ALK rearrangements in distinguishing inflammatory myofibroblastic tumor from malignant spindle cell lesions of the urinary bladder. *Modern Pathology* , **2007**, 20, 592-603	9.8	83
424	Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016. *JAMA Oncology*, **2017**, 3, 1257-1265	13.4	82
423	Preclinical validation of fluorescence in situ hybridization assays for clinical practice. *Genetics in Medicine*, **2006**, 8, 16-23	8.1	81
422	Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups. *Blood*, **2016**, 127, 1551-8	2.2	81
421	Translocation t(11;14) and survival of patients with light chain (AL) amyloidosis. *Haematologica*, **2009**, 94, 380-6	6.6	80
420	CD25 expression status improves prognostic risk classification in AML independent of established biomarkers: ECOG phase 3 trial, E1900. *Blood*, **2012**, 120, 2297-306	2.2	78
419	SETBP1 mutations in 415 patients with primary myelofibrosis or chronic myelomonocytic leukemia: independent prognostic impact in CMML. *Leukemia*, **2013**, 27, 2100-2	10.7	75
418	Analysis of Intratumoral Heterogeneity and Amplification Status in Breast Carcinomas With Equivocal (2+) HER-2 Immunostaining. *American Journal of Clinical Pathology*, **2005**, 124, 273-281	1.9	73
417	WHO-defined 'myelodysplastic syndrome with isolated del(5q)' in 88 consecutive patients: survival data, leukemic transformation rates and prevalence of JAK2, MPL and IDH mutations. *Leukemia*, **2010**, 24, 1283-9	10.7	72
416	Integrative epigenomic analysis identifies biomarkers and therapeutic targets in adult B-acute lymphoblastic leukemia. *Cancer Discovery*, **2012**, 2, 1004-23	24.4	70
415	Morphologic Features of ALK-negative Anaplastic Large Cell Lymphomas With DUSP22 Rearrangements. *American Journal of Surgical Pathology*, **2016**, 40, 36-43	6.7	70
414	and rearrangements predict outcome of ALK-negative anaplastic large cell lymphoma: a Danish cohort study. *Blood*, **2017**, 130, 554-557	2.2	68
413	Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts. *Leukemia*, **2018**, 32, 1200-1210	10.7	68
412	Change in Pattern of HER2 Fluorescent in Situ Hybridization (FISH) Results in Breast Cancers Submitted for FISH Testing: Experience of a Reference Laboratory Using US Food and Drug Administration Criteria and American Society of Clinical Oncology and College of American Pathologists Guidelines. *Journal of Clinical Oncology*, **2016**, 34, 3502-3510	2.2	68
411	Revised cytogenetic risk stratification in primary myelofibrosis: analysis based on 1002 informative patients. *Leukemia*, **2018**, 32, 1189-1199	10.7	65
410	Genetic subtyping of breast implant-associated anaplastic large cell lymphoma. *Blood*, **2018**, 132, 544-547	2.2	60

409	Clonally related follicular lymphomas and Langerhans cell neoplasms: expanding the spectrum of transdifferentiation. *American Journal of Surgical Pathology*, **2013**, 37, 978-86	6.7	60
408	Molecular diagnosis of Ewing's sarcoma/primitive neuroectodermal tumor in formalin-fixed paraffin-embedded tissues by RT-PCR and fluorescence in situ hybridization. *Diagnostic Molecular Pathology*, **2005**, 14, 23-8		60
407	Prognostic irrelevance of ring sideroblast percentage in World Health Organization-defined myelodysplastic syndromes without excess blasts. *Blood*, **2012**, 119, 5674-7	2.2	59
406	Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera. *British Journal of Haematology*, **2020**, 189, 291-302	4.5	58
405	Primary myelodysplastic syndrome with normal cytogenetics: utility of 'FISH panel testing' and M-FISH. *Leukemia Research*, **2002**, 26, 235-40	2.7	57
404	Rosette-forming glioneuronal tumor: report of a chiasmal-optic nerve example in neurofibromatosis type 1: special pathology report. *Neurosurgery*, **2009**, 64, E771-2; discussion E772	3.2	56
403	Cytogenetic studies at diagnosis in polycythemia vera: clinical and JAK2V617F allele burden correlates. *European Journal of Haematology*, **2008**, 80, 197-200	3.8	56
402	Extending Jak2V617F and MplW515 mutation analysis to single hematopoietic colonies and B and T lymphocytes. *Stem Cells*, **2007**, 25, 2358-62	5.8	55
401	Predictors of survival in refractory anemia with ring sideroblasts and thrombocytosis (RARS-T) and the role of next-generation sequencing. *American Journal of Hematology*, **2016**, 91, 492-8	7.1	55
400	Targeted next-generation sequencing in blast phase myeloproliferative neoplasms. *Blood Advances*, **2018**, 2, 370-380	7.8	55
399	Biologic and genetic characterization of the novel amyloidogenic lambda light chain-secreting human cell lines, ALMC-1 and ALMC-2. *Blood*, **2008**, 112, 1931-41	2.2	54
398	Evidence that descendants of three founders constitute about 25% of hemophilia B in the United States. *Genomics*, **1991**, 10, 1093-6	4.3	54
397	Driver mutations and prognosis in primary myelofibrosis: Mayo-Careggi MPN alliance study of 1,095 patients. *American Journal of Hematology*, **2018**, 93, 348-355	7.1	54
396	Autologous transplantation gives encouraging results for young adults with favorable-risk acute myeloid leukemia, but is not improved with gemtuzumab ozogamicin. *Blood*, **2011**, 117, 5306-13	2.2	53
395	Cytogenetic abnormalities in essential thrombocythemia: prevalence and prognostic significance. *European Journal of Haematology*, **2009**, 83, 17-21	3.8	53
394	Evidence for cytogenetic and fluorescence in situ hybridization risk stratification of newly diagnosed multiple myeloma in the era of novel therapie. *Mayo Clinic Proceedings*, **2010**, 85, 532-7	6.4	52
393	Section E9 of the American College of Medical Genetics technical standards and guidelines: fluorescence in situ hybridization. *Genetics in Medicine*, **2011**, 13, 667-75	8.1	52
392	Reflex fluorescent in situ hybridization testing for unsuccessful product of conception cultures: a retrospective analysis of 5555 samples attempted by conventional cytogenetics and fluorescent in situ hybridization. *Genetics in Medicine*, **2011**, 13, 545-52	8.1	52

391	New highly sensitive fluorescence in situ hybridization method to detect PML/RARA fusion in acute promyelocytic leukemia. *Cancer Genetics and Cytogenetics*, **2003**, 145, 144-51		52
390	Pituitary blastoma. *Acta Neuropathologica*, **2008**, 116, 657-66	14.3	51
389	3023 Mayo Clinic Patients With Myeloproliferative Neoplasms: Risk-Stratified Comparison of Survival and Outcomes Data Among Disease Subgroups. *Mayo Clinic Proceedings*, **2019**, 94, 599-610	6.4	50
388	Targeted next-generation sequencing in myelodysplastic syndromes and prognostic interaction between mutations and IPSS-R. *American Journal of Hematology*, **2017**, 92, 1311-1317	7.1	50
387	Azacitidine with or without Entinostat for the treatment of therapy-related myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup study. *British Journal of Haematology*, **2016**, 172, 384-91	4.5	49
386	Histiocytoid Sweet syndrome may indicate leukemia cutis: a novel application of fluorescence in situ hybridization. *Journal of the American Academy of Dermatology*, **2014**, 70, 1021-7	4.5	49
385	C-MYC alterations and association with patient outcome in early-stage HER2-positive breast cancer from the north central cancer treatment group N9831 adjuvant trastuzumab trial. *Journal of Clinical Oncology*, **2011**, 29, 651-9	2.2	49
384	Utility of subtelomeric fluorescent DNA probes for detection of chromosome anomalies in 425 patients. *Genetics in Medicine*, **2003**, 5, 28-34	8.1	49
383	DNMT3A mutations are associated with inferior overall and leukemia-free survival in chronic myelomonocytic leukemia. *American Journal of Hematology*, **2017**, 92, 56-61	7.1	48
382	U2AF1 mutation types in primary myelofibrosis: phenotypic and prognostic distinctions. *Leukemia*, **2018**, 32, 2274-2278	10.7	47
381	The oncogenic transcription factor IRF4 is regulated by a novel CD30/NF-B positive feedback loop in peripheral T-cell lymphoma. *Blood*, **2015**, 125, 3118-27	2.2	47
380	Karyotype complements the International Prognostic Scoring System for primary myelofibrosis. *European Journal of Haematology*, **2009**, 82, 255-9	3.8	47
379	Next-generation sequencing in systemic mastocytosis: Derivation of a mutation-augmented clinical prognostic model for survival. *American Journal of Hematology*, **2016**, 91, 888-93	7.1	47
378	Treatment-influenced associations of PML-RAR mutations, FLT3 mutations, and additional chromosome abnormalities in relapsed acute promyelocytic leukemia. *Blood*, **2012**, 120, 2098-108	2.2	46
377	Recurrent fusions in indolent T-cell lymphoproliferative disorder of the gastrointestinal tract. *Blood* , **2018**, 131, 2262-2266	2.2	45
376	Very poor long-term survival in past and more recent studies for relapsed AML patients: The ECOG-ACRIN experience. *American Journal of Hematology*, **2018**, 93, 1074-1081	7.1	45
375	Blast transformation in chronic myelomonocytic leukemia: Risk factors, genetic features, survival, and treatment outcome. *American Journal of Hematology*, **2015**, 90, 411-6	7.1	45
374	Pediatric histiocytic sarcoma clonally related to precursor B-cell acute lymphoblastic leukemia with homozygous deletion of CDKN2A encoding p16INK4A. *Pediatric Blood and Cancer*, **2011**, 56, 307-10	3	45

373	Reported in vivo splice-site mutations in the factor IX gene: severity of splicing defects and a hypothesis for predicting deleterious splice donor mutations. *Human Mutation*, **1999**, 13, 221-31	4.7	45
372	Molecular profiling reveals immunogenic cues in anaplastic large cell lymphomas with rearrangements. *Blood*, **2018**, 132, 1386-1398	2.2	44
371	The factor IX gene as a model for analysis of human germline mutations: an update. *Human Molecular Genetics*, **1996**, 5 Spec No, 1505-14	5.6	43
370	Recurrent IDH mutations in high-risk myelodysplastic syndrome or acute myeloid leukemia with isolated del(5q). *Leukemia*, **2010**, 24, 1370-2	10.7	42
369	Targeted next generation sequencing and identification of risk factors in World Health Organization defined atypical chronic myeloid leukemia. *American Journal of Hematology*, **2017**, 92, 542-548	7.1	41
368	Mayo alliance prognostic system for mastocytosis: clinical and hybrid clinical-molecular models. *Blood Advances*, **2018**, 2, 2964-2972	7.8	40
367	ALK-1 protein expression and ALK gene rearrangements aid in the diagnosis of inflammatory myofibroblastic tumors of the female genital tract. *Archives of Pathology and Laboratory Medicine*, **2012**, 136, 623-6	5	39
366	Therapy related-chronic myelomonocytic leukemia (CMML): Molecular, cytogenetic, and clinical distinctions from de novo CMML. *American Journal of Hematology*, **2018**, 93, 65-73	7.1	37
365	The pattern of spontaneous germ-line mutation: relative rates of mutation at or near CpG dinucleotides in the factor IX gene. *Human Genetics*, **1993**, 91, 496-503	6.3	37
364	Calreticulin variant stratified driver mutational status and prognosis in essential thrombocythemia. *American Journal of Hematology*, **2016**, 91, 503-6	7.1	37
363	Development of acute megakaryoblastic leukemia in Down syndrome is associated with sequential epigenetic changes. *Blood*, **2013**, 122, e33-43	2.2	36
362	Establishment and characterization of a novel Waldenstrom macroglobulinemia cell line, MWCL-1. *Blood*, **2011**, 117, e190-7	2.2	36
361	Impact of American Society of Clinical Oncology/College of American Pathologists guideline recommendations on HER2 interpretation in breast cancer. *Human Pathology*, **2010**, 41, 103-6	3.7	36
360	Mutations and thrombosis in essential thrombocythemia: prognostic interaction with age and thrombosis history. *European Journal of Haematology*, **2015**, 94, 31-6	3.8	35
359	Spectrum of autoimmune diseases and systemic inflammatory syndromes in patients with chronic myelomonocytic leukemia. *Leukemia and Lymphoma*, **2017**, 58, 1488-1493	1.9	35
358	Novel recurrent mutations in ethanolamine kinase 1 (ETNK1) gene in systemic mastocytosis with eosinophilia and chronic myelomonocytic leukemia. *Blood Cancer Journal*, **2015**, 5, e275	7	35
357	Analysis of genetic abnormalities provides insights into genetic evolution of hyperdiploid myeloma. *Genes Chromosomes and Cancer*, **2006**, 45, 1111-20	5	35
356	Mutations and prognosis in myelodysplastic syndromes: karyotype-adjusted analysis of targeted sequencing in 300 consecutive cases and development of a genetic risk model. *American Journal of Hematology*, **2018**, 93, 691-697	7.1	34

355	Intralymphatic cutaneous anaplastic large cell lymphoma/lymphomatoid papulosis: expanding the spectrum of CD30-positive lymphoproliferative disorders. *American Journal of Surgical Pathology*, **2014**, 38, 1203-11	6.7	34
354	A past mutation at isoleucine 397 is now a common cause of moderate/mild haemophilia B. *British Journal of Haematology*, **1990**, 75, 212-6	4.5	33
353	Expression of p63 protein in anaplastic large cell lymphoma: implications for genetic subtyping. *Human Pathology*, **2017**, 64, 19-27	3.7	31
352	Monocytosis in polycythemia vera: Clinical and molecular correlates. *American Journal of Hematology*, **2017**, 92, 640-645	7.1	31
351	Inferior survival in high-grade B-cell lymphoma with and and/or rearrangements is not associated with gene rearrangements. *Haematologica*, **2018**, 103, 1899-1907	6.6	31
350	Chromosome 8p11.2 translocations: prevalence, FISH analysis for FGFR1 and MYST3, and clinicopathologic correlates in a consecutive cohort of 13 cases from a single institution. *American Journal of Hematology*, **2010**, 85, 238-42	7.1	31
349	Myeloproliferative neoplasms in the young: Mayo Clinic experience with 361 patients age 40 years or younger. *American Journal of Hematology*, **2018**, 93, 1474-1484	7.1	31
348	EZH2 mutations in chronic myelomonocytic leukemia cluster with ASXL1 mutations and their co-occurrence is prognostically detrimental. *Blood Cancer Journal*, **2018**, 8, 12	7	30
347	Chronic lymphocytic leukemia with t(14;19)(q32;q13) is characterized by atypical morphologic and immunophenotypic features and distinctive genetic features. *American Journal of Clinical Pathology* , **2011**, 135, 686-96	1.9	30
346	Evaluation of revised IPSS cytogenetic risk stratification and prognostic impact of monosomal karyotype in 783 patients with primary myelodysplastic syndromes. *American Journal of Hematology*, **2013**, 88, 690-3	7.1	29
345	t(8;9)(p22;p24)/PCM1-JAK2 activates SOCS2 and SOCS3 via STAT5. *PLoS ONE*, **2013**, 8, e53767	3.7	29
344	Rearrangements and amplification of IER3 (IEX-1) represent a novel and recurrent molecular abnormality in myelodysplastic syndromes. *Cancer Research*, **2009**, 69, 7518-23	10.1	29
343	Leukemic transformation among 1306 patients with primary myelofibrosis: risk factors and development of a predictive model. *Blood Cancer Journal*, **2019**, 9, 12	7	28
342	Desmoplastic small round cell tumor of the central nervous system: report of two cases and review of the literature. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2009**, 454, 431-9	5.1	28
341	CCND1 rearrangements and cyclin D1 overexpression in renal oncocytomas: frequency, clinicopathologic features, and utility in differentiation from chromophobe renal cell carcinoma. *Human Pathology*, **2009**, 40, 1296-303	3.7	28
340	Functioning paraganglioma and gastrointestinal stromal tumor of the jejunum in three women: syndrome or coincidence. *American Journal of Surgical Pathology*, **2006**, 30, 42-9	6.7	28
339	Germline mutations in the factor IX gene: a comparison of the pattern in Caucasians and non-Caucasians. *Human Molecular Genetics*, **1993**, 2, 293-8	5.6	28
338	Suboptimal response rates to hypomethylating agent therapy in chronic myelomonocytic leukemia; a single institutional study of 121 patients. *American Journal of Hematology*, **2019**, 94, 767-779	7.1	27

337	Momelotinib therapy for myelofibrosis: a 7-year follow-up. *Blood Cancer Journal*, **2018**, 8, 29	7	27
336	Chronic lymphocytic leukemia With t(2;14)(p16;q32) involves the BCL11A and IgH genes and is associated with atypical morphologic features and unmutated IgVH genes. *American Journal of Clinical Pathology*, **2009**, 131, 663-70	1.9	27
335	Inherited interstitial deletion of chromosomes 5p and 16q without apparent phenotypic effect: further confirmation. *Prenatal Diagnosis*, **2000**, 20, 144-8; discussion 149-51	3.2	27
334	Clinical characteristics and treatment outcomes of newly diagnosed multiple myeloma with chromosome 1q abnormalities. *Blood Advances*, **2020**, 4, 3509-3519	7.8	27
333	Sex and degree of severity influence the prognostic impact of anemia in primary myelofibrosis: analysis based on 1109 consecutive patients. *Leukemia*, **2018**, 32, 1254-1258	10.7	26
332	Allogeneic hematopoietic stem cell transplant overcomes the adverse survival effect of very high risk and unfavorable karyotype in myelofibrosis. *American Journal of Hematology*, **2018**, 93, 649-654	7.1	26
331	A compendium of cytogenetic abnormalities in myelofibrosis: molecular and phenotypic correlates in 826 patients. *British Journal of Haematology*, **2015**, 169, 71-6	4.5	26
330	Clonal relationship between precursor B-cell acute lymphoblastic leukemia and histiocytic sarcoma: a case report and discussion in the context of similar cases. *Leukemia Research*, **2010**, 34, e71-3	2.7	25
329	Comparison of fluorescence in situ hybridization, p57 immunostaining, flow cytometry, and digital image analysis for diagnosing molar and nonmolar products of conception. *American Journal of Clinical Pathology*, **2010**, 133, 196-204	1.9	24
328	Image analysis of HER2 immunohistochemical staining. Reproducibility and concordance with fluorescence in situ hybridization of a laboratory-validated scoring technique. *American Journal of Clinical Pathology*, **2012**, 137, 270-6	1.9	24
327	Isolated trisomy 15: a clonal chromosome abnormality in bone marrow with doubtful hematologic significance. *American Journal of Clinical Pathology*, **2008**, 129, 478-85	1.9	24
326	Recurrent mutations in ALK-negative anaplastic large cell lymphoma. *Blood*, **2019**, 133, 2776-2789	2.2	23
325	Epidemiology of adult acute myeloid leukemia: Impact of exposures on clinical phenotypes and outcomes after therapy. *Cancer Epidemiology*, **2015**, 39, 1084-92	2.8	23
324	Monocytosis is a powerful and independent predictor of inferior survival in primary myelofibrosis. *British Journal of Haematology*, **2018**, 183, 835-838	4.5	23
323	An MLL-SEPT9 fusion and t(11;17)(q23;q25) associated with de novo myelodysplastic syndrome. *Leukemia Research*, **2007**, 31, 1145-8	2.7	23
322	Mate pair sequencing improves detection of genomic abnormalities in acute myeloid leukemia. *European Journal of Haematology*, **2019**, 102, 87-96	3.8	23
321	Natural history of multiple myeloma with de novo del(17p). *Blood Cancer Journal*, **2019**, 9, 32	7	22
320	Polyclonal immunoglobulin free light chain levels predict survival in myeloid neoplasms. *Journal of Clinical Oncology*, **2012**, 30, 1087-94	2.2	22

319	Splenic small B-cell lymphoma with IGH/BCL3 translocation. *Human Pathology*, **2006**, 37, 218-30	3.7	22
318	Chronic myelomonocytic leukemia in younger patients: molecular and cytogenetic predictors of survival and treatment outcome. *Blood Cancer Journal*, **2015**, 5, e270	7	21
317	Isochromosome 12p and polysomy 12 in primary central nervous system germ cell tumors: frequency and association with clinicopathologic features. *Human Pathology*, **2010**, 41, 232-8	3.7	21
316	Chromosome 1 abnormalities in myeloid malignancies: a literature survey and karyotype-phenotype associations. *European Journal of Haematology*, **2010**, 84, 191-200	3.8	21
315	Chromosome 9p24 abnormalities: prevalence, description of novel JAK2 translocations, JAK2V617F mutation analysis and clinicopathologic correlates. *European Journal of Haematology*, **2010**, 84, 518-24	3.8	21
314	Deletions with inversions: report of a mutation and review of the literature. *Human Mutation*, **1993**, 2, 53-7	4.7	21
313	Nucleophosmin 1 (NPM1) mutations in chronic myelomonocytic leukemia and their prognostic relevance. *American Journal of Hematology*, **2017**, 92, E614-E618	7.1	20
312	Impact of acquired del(17p) in multiple myeloma. *Blood Advances*, **2019**, 3, 1930-1938	7.8	20
311	A comparison of clinical and molecular characteristics of patients with systemic mastocytosis with chronic myelomonocytic leukemia to CMML alone. *Leukemia*, **2018**, 32, 1850-1856	10.7	19
310	Blast phase chronic myelomonocytic leukemia: Mayo-MDACC collaborative study of 171 cases. *Leukemia*, **2018**, 32, 2512-2518	10.7	19
309	Evaluation of a commercially available focused aCGH platform for the detection of constitutional chromosome anomalies. *American Journal of Medical Genetics, Part A*, **2007**, 143A, 2357-70	2.5	19
308	Analysis of intratumoral heterogeneity and amplification status in breast carcinomas with equivocal (2+) HER-2 immunostaining. *American Journal of Clinical Pathology*, **2005**, 124, 273-81	1.9	19
307	ASXL1 and CBL mutations are independently predictive of inferior survival in advanced systemic mastocytosis. *British Journal of Haematology*, **2016**, 175, 534-536	4.5	19
306	A randomized trial of three novel regimens for recurrent acute myeloid leukemia demonstrates the continuing challenge of treating this difficult disease. *American Journal of Hematology*, **2019**, 94, 111-117	7.1	19
305	Evaluation of Revised International Staging System (R-ISS) for transplant-eligible multiple myeloma patients. *Annals of Hematology*, **2018**, 97, 1453-1462	3	18
304	Prognostic significance of interphase FISH in monoclonal gammopathy of undetermined significance. *Leukemia*, **2018**, 32, 1811-1815	10.7	18
303	Prefibrotic versus overtly fibrotic primary myelofibrosis: clinical, cytogenetic, molecular and prognostic comparisons. *British Journal of Haematology*, **2018**, 182, 594-597	4.5	18
302	Gender and survival in essential thrombocythemia: A two-center study of 1,494 patients. *American Journal of Hematology*, **2017**, 92, 1193-1197	7.1	18

301	Isolated del(5q) in myeloid malignancies: clinicopathologic and molecular features in 143 consecutive patients. *American Journal of Hematology*, **2011**, 86, 393-8	7.1	18
300	Utility of peripheral blood dual color, double fusion fluorescent in situ hybridization for BCR/ABL fusion to assess cytogenetic remission status in chronic myeloid leukemia. *Leukemia and Lymphoma* , **2006**, 47, 2055-61	1.9	18
299	A mutation in the 3' untranslated region of the factor IX gene in four families with hemophilia B. *Human Molecular Genetics*, **1993**, 2, 1309-10	5.6	18
298	Mate pair sequencing outperforms fluorescence in situ hybridization in the genomic characterization of multiple myeloma. *Blood Cancer Journal*, **2019**, 9, 103	7	18
297	Mutations and karyotype predict treatment response in myelodysplastic syndromes. *American Journal of Hematology*, **2018**, 93, 1420-1426	7.1	18
296	Validation of the WHO-defined 20% circulating blasts threshold for diagnosis of leukemic transformation in primary myelofibrosis. *Blood Cancer Journal*, **2018**, 8, 57	7	17
295	Cytogenetic abnormalities in systemic mastocytosis: WHO subcategory-specific incidence and prognostic impact among 348 informative cases. *American Journal of Hematology*, **2018**, 93, 1461-1466	7.1	17
294	Risk factors and a prognostic model for postsplenectomy survival in myelofibrosis. *American Journal of Hematology*, **2017**, 92, 1187-1192	7.1	17
293	Familial 22q11.2 deletions in DiGeorge/velocardiofacial syndrome are predominantly smaller than the commonly observed 3Mb. *Genetics in Medicine*, **2004**, 6, 517-20	8.1	17
292	Cytogenetic abnormalities in multiple myeloma: association with disease characteristics and treatment response. *Blood Cancer Journal*, **2020**, 10, 82	7	17
291	Clinicopathologic characteristics, prognostication and treatment outcomes for myelodysplastic/myeloproliferative neoplasm, unclassifiable (MDS/MPN-U): Mayo Clinic-Moffitt Cancer Center study of 135 consecutive patients. *Leukemia*, **2020**, 34, 656-661	10.7	17
290	Conventional karyotyping and fluorescence in situ hybridization: an effective utilization strategy in diagnostic adult acute myeloid leukemia. *American Journal of Clinical Pathology*, **2015**, 143, 873-8	1.9	16
289	The B cell antigen receptor in atypical chronic lymphocytic leukemia with t(14;19)(q32;q13) demonstrates remarkable stereotypy. *International Journal of Cancer*, **2011**, 128, 2759-64	7.5	16
288	Interphase FISH to detect PBX1/E2A fusion resulting from the der(19)t(1;19)(q23;p13.3) or t(1;19)(q23;p13.3) in paediatric patients with acute lymphoblastic leukaemia. *British Journal of Haematology*, **2005**, 129, 45-52	4.5	16
287	KMT2A (MLL) rearrangements observed in pediatric/young adult T-lymphoblastic leukemia/lymphoma: A 10-year review from a single cytogenetic laboratory. *Genes Chromosomes and Cancer*, **2018**, 57, 541-546	5	16
286	Independent Prognostic Significance of Monosomy 17 and Impact of Karyotype Complexity in Monosomal Karyotype/Complex Karyotype Acute Myeloid Leukemia: Results from Four ECOG-ACRIN Prospective Therapeutic Trials. *Leukemia Research*, **2017**, 59, 55-64	2.7	15
285	Development of a dual-color, double fusion FISH assay to detect RPN1/EVI1 gene fusion associated with inv(3), t(3;3), and ins(3;3) in patients with myelodysplasia and acute myeloid leukemia. *American Journal of Hematology*, **2010**, 85, 569-74	7.1	15
284	Primary myelofibrosis is the most frequent myeloproliferative neoplasm associated with del(5q): clinicopathologic comparison of del(5q)-positive and -negative cases. *Leukemia Research*, **2008**, 32, 1927-30	2.7	15

283	How precisely can data from transgenic mouse mutation-detection systems be extrapolated to humans?: lesions from the human factor IX gene. *Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis*, **1994**, 307, 517-31	3.3	15
282	Molecular Epidemiology of Factor IX Germline Mutations in Mexican Hispanics: Pattern of Mutation and Potential Founder Effects. *Thrombosis and Haemostasis*, **1995**, 74, 1416-1422	7	15
281	Cytogenetic findings in WHO-defined polycythaemia vera and their prognostic relevance. *British Journal of Haematology*, **2018**, 182, 437-440	4.5	14
280	Mayo Alliance Prognostic Model for Myelodysplastic Syndromes: Integration of Genetic and Clinical Information. *Mayo Clinic Proceedings*, **2018**, 93, 1363-1374	6.4	14
279	Atypical generalized eruptive histiocytosis clonally related to chronic myelomonocytic leukemia with loss of Y chromosome. *Journal of Cutaneous Pathology*, **2013**, 40, 725-9	1.7	14
278	Validation of a new three-color fluorescence in situ hybridization (FISH) method to detect CHIC2 deletion, FIP1L1/PDGFRA fusion and PDGFRA translocations. *Leukemia Research*, **2009**, 33, 843-6	2.7	14
277	Trisomy 13: prevalence and clinicopathologic correlates of another potentially lenalidomide-sensitive cytogenetic abnormality. *Blood*, **2009**, 113, 1200-1	2.2	14
276	Nearly identical near-haploid karyotype in a peritoneal mesothelioma and a retroperitoneal malignant peripheral nerve sheath tumor. *Cancer Genetics and Cytogenetics*, **2010**, 202, 123-8		14
275	Chromosome 5q deletion: specific diagnoses and cytogenetic details among 358 consecutive cases from a single institution. *Leukemia Research*, **2008**, 32, 407-11	2.7	14
274	Analysis of HER2 gene amplification using an automated fluorescence in situ hybridization signal enumeration system. *Journal of Molecular Diagnostics*, **2007**, 9, 144-50	5.1	14
273	Bone Marrow Conventional Karyotyping and Fluorescence In Situ Hybridization: Defining an Effective Utilization Strategy for Evaluation of Myelodysplastic Syndromes. *American Journal of Clinical Pathology*, **2016**, 146, 86-94	1.9	14
272	FISH identifies a KAT6A/CREBBP fusion caused by a cryptic insertional t(8;16) in a case of spontaneously remitting congenital acute myeloid leukemia with a normal karyotype. *Pediatric Blood and Cancer*, **2017**, 64, e26450	3	13
271	Prognostic interaction between bone marrow morphology and SF3B1 and ASXL1 mutations in myelodysplastic syndromes with ring sideroblasts. *Blood Cancer Journal*, **2018**, 8, 18	7	13
270	LMO2 Is a Specific Marker of T-Lymphoblastic Leukemia/Lymphoma. *American Journal of Clinical Pathology*, **2016**, 145, 180-90	1.9	13
269	Mutations and karyotype in myelodysplastic syndromes: TP53 clusters with monosomal karyotype, RUNX1 with trisomy 21, and SF3B1 with inv(3)(q21q26.2) and del(11q). *Blood Cancer Journal*, **2017**, 7, 658	7	13
268	Automated Duet spot counting system and manual technologist scoring using dual-fusion fluorescence in situ hybridization (D-FISH) strategy: comparison and application to FISH minimal residual disease testing in patients with chronic myeloid leukemia. *Cancer Genetics and Cytogenetics* , **2007**, 175, 8-18		13
267	Clinical correlates, prognostic impact and survival outcomes in chronic myelomonocytic leukemia patients with the V617F mutation. *Haematologica*, **2019**, 104, e236-e239	6.6	13
266	MPL-mutated essential thrombocythemia: a morphologic reappraisal. *Blood Cancer Journal*, **2018**, 8, 1217		13

265	A case of nonleukemic myeloid sarcoma with FIP1L1-PDGFRA rearrangement: an unusual presentation of a rare disease. *American Journal of Surgical Pathology*, **2013**, 37, 147-51	6.7	12
264	A novel report of cig-FISH and cytogenetics in POEMS syndrome. *American Journal of Hematology*, **2008**, 83, 840-1	7.1	12
263	Prognostic impact of ASXL1 mutations in patients with myelodysplastic syndromes and multilineage dysplasia with or without ring sideroblasts. *Leukemia Research*, **2018**, 71, 60-62	2.7	11
262	Clinicopathologic and genetic characterization of follicular lymphomas presenting in the ovary reveals 2 distinct subgroups. *American Journal of Surgical Pathology*, **2011**, 35, 1691-9	6.7	11
261	Successful treatment of a child with T/myeloid acute bilineal leukemia associated with TLX3/BCL11B fusion and 9q deletion. *Pediatric Blood and Cancer*, **2011**, 56, 467-9	3	11
260	Two novel factor IX promoter mutations: incremental progress towards 'saturation in vivo mutagenesis' of a human promoter region. *Human Molecular Genetics*, **1995**, 4, 769-70	5.6	11
259	Concurrent activating KIT mutations in systemic mastocytosis. *British Journal of Haematology*, **2016**, 173, 153-6	4.5	11
258	Acute leukemias harboring KMT2A/MLLT10 fusion: a 10-year experience from a single genomics laboratory. *Genes Chromosomes and Cancer*, **2019**, 58, 567-577	5	11
257	Characterization of a cryptic rearrangement in a case of mantle cell lymphoma with negative FISH studies. *Blood Advances*, **2019**, 3, 1298-1302	7.8	11
256	Chromosomal rearrangements and copy number abnormalities of TP63 correlate with p63 protein expression in lung adenocarcinoma. *Modern Pathology*, **2015**, 28, 359-66	9.8	10
255	Primary Myelodysplastic Syndromes: The Mayo Clinic Experience With 1000 Patients. *Mayo Clinic Proceedings*, **2015**, 90, 1623-38	6.4	10
254	Morphologically occult systemic mastocytosis in bone marrow: clinicopathologic features and an algorithmic approach to diagnosis. *American Journal of Clinical Pathology*, **2015**, 144, 493-502	1.9	10
253	High level MYC amplification in B-cell lymphomas: is it a marker of aggressive disease?. *Blood Cancer Journal*, **2020**, 10, 5	7	10
252	Correlation of CYP2B6, CYP2C19, ABCC4 and SOD2 genotype with outcomes in allogeneic blood and marrow transplant patients. *Leukemia Research*, **2012**, 36, 59-66	2.7	10
251	TP53 mutations and polymorphisms in primary myelofibrosis. *American Journal of Hematology*, **2012**, 87, 204-6	7.1	10
250	Impact of Alemtuzumab Therapy and Route of Administration in T-Prolymphocytic Leukemia: A Single-Center Experience. *Clinical Lymphoma, Myeloma and Leukemia*, **2015**, 15, 699-704	2	10
249	Microgranular variant of acute promyelocytic leukemia with normal conventional cytogenetics, negative PML/RARA FISH and positive PML/RARA transcripts by RT-PCR. *Cancer Genetics*, **2011**, 204, 522-3	2.3	10
248	Postimatinib therapy emergence of a new JAK2V617F clone and subsequent development of overt polycythemia vera in a patient with chronic myelogenous leukaemia. *European Journal of Haematology*, **2010**, 85, 86-7	3.8	10

247	Germline mutations in Peruvian patients with hemophilia B: pattern of mutation in AmerIndians is similar to the putative endogenous germline pattern. *Human Mutation*, **1998**, 11, 372-6	4.7	10
246	Comprehensive validation of array comparative genomic hybridization platforms: how much is enough?. *Genetics in Medicine*, **2007**, 9, 632-41	8.1	10
245	Absence of somatic mosaicism in 17 families with hemophilia B: an analysis with a sensitivity 10- to 1000-fold greater than that of sequencing gels. *Human Genetics*, **1996**, 98, 539-45	6.3	10
244	"Cryptic" dinucleotide polymorphism in the 3' region of the factor IX gene shows substantial variation among different populations. *Human Genetics*, **1994**, 93, 357-8	6.3	10
243	Screening for ASXL1 and SRSF2 mutations is imperative for treatment decision-making in otherwise low or intermediate-1 risk patients with myelofibrosis. *British Journal of Haematology*, **2018**, 183, 678-681	4.5	10
242	Infrequent occurrence of TET1, TET3, and ASXL2 mutations in myelodysplastic/myeloproliferative neoplasms. *Blood Cancer Journal*, **2018**, 8, 32	7	9
241	The Utilization of Chromosomal Microarray Technologies for Hematologic Neoplasms: An ACLPS Critical Review. *American Journal of Clinical Pathology*, **2018**, 150, 375-384	1.9	9
240	Characterization of TCF3 rearrangements in pediatric B-lymphoblastic leukemia/lymphoma by mate-pair sequencing (MPseq) identifies complex genomic rearrangements and a novel TCF3/TEF gene fusion. *Blood Cancer Journal*, **2019**, 9, 81	7	9
239	Development of five dual-color, double-fusion fluorescence in situ hybridization assays for the detection of common MLL translocation partners. *Journal of Molecular Diagnostics*, **2010**, 12, 441-52	5.1	9
238	Targeted Next-Generation Sequencing in Polycythemia Vera and Essential Thrombocythemia. *Blood* , **2015**, 126, 354-354	2.2	9
237	Primary central nervous system B cell lymphoma with features intermediate between diffuse large B cell lymphoma and Burkitt lymphoma. *International Journal of Clinical and Experimental Pathology* , **2012**, 5, 72-6	1.4	9
236	Application of thrombolytic drugs on clotted blood and bone marrow specimens to generate usable cells for cytogenetic analyses. *Archives of Pathology and Laboratory Medicine*, **2011**, 135, 915-9	5	9
235	Implications of MYC Rearrangements in Newly Diagnosed Multiple Myeloma. *Clinical Cancer Research*, **2020**, 26, 6581-6588	12.9	9
234	A phase II randomized trial comparing standard and low dose rituximab combined with alemtuzumab as initial treatment of progressive chronic lymphocytic leukemia in older patients: a trial of the ECOG-ACRIN cancer research group (E1908). *American Journal of Hematology*, **2016**, 91, 308-12	7.1	9
233	Elucidating a false-negative break-apart fluorescence in situ hybridization probe study by next-generation sequencing in a patient with high-grade B-cell lymphoma with and rearrangements. *Journal of Physical Education and Sports Management*, **2019**, 5,	2.8	8
232	Substratification of patients with newly diagnosed standard-risk multiple myeloma. *British Journal of Haematology*, **2019**, 185, 254-260	4.5	8
231	A prospective evaluation of vitamin B1 (thiamine) level in myeloproliferative neoplasms: clinical correlations and impact of JAK2 inhibitor therapy. *Blood Cancer Journal*, **2019**, 9, 11	7	8
230	Development of a prognostically relevant cachexia index in primary myelofibrosis using serum albumin and cholesterol levels. *Blood Advances*, **2018**, 2, 1980-1984	7.8	8

229	Expression of the chemokine receptor gene, CCR8, is associated With DUSP22 rearrangements in anaplastic large cell lymphoma. *Applied Immunohistochemistry and Molecular Morphology*, **2015**, 23, 580-9	1.9	8
228	Cutaneous extramedullary plasmacytoma: clinical, prognostic, and interphase cytogenetic analysis. *American Journal of Dermatopathology*, **2013**, 35, 357-63	0.9	8
227	Early thrombotic events and preemptive systemic anticoagulation following splenectomy for myelofibrosis. *American Journal of Hematology*, **2018**, 93, E235-E238	7.1	7
226	Splenectomy in patients with chronic myelomonocytic leukemia: Indications, histopathological findings and clinical outcomes in a single institutional series of thirty-nine patients. *American Journal of Hematology*, **2018**, 93, 1347-1357	7.1	7
225	A case of hairy cell leukemia with CCND1-IGH@ translocation: indolent non-nodal mantle cell lymphoma revisited. *American Journal of Surgical Pathology*, **2011**, 35, 1080-4	6.7	7
224	Peripheral blood cytogenetic studies in hematological neoplasms: predictors of obtaining metaphases for analysis. *European Journal of Haematology*, **2008**, 80, 318-21	3.8	7
223	Metaphase cytogenetics and plasma cell proliferation index for risk stratification in newly diagnosed multiple myeloma. *Blood Advances*, **2020**, 4, 2236-2244	7.8	7
222	Molecular classification improves risk assessment in adult BCR-ABL1-negative B-ALL. *Blood*, **2021**, 138, 948-958	2.2	7
221	Tetraploidy is associated with poor prognosis at diagnosis in multiple myeloma. *American Journal of Hematology*, **2019**, 94, E117-E120	7.1	6
220	Hyperhaploid plasma cell myeloma characterized by poor outcome and monosomy 17 with frequently co-occurring TP53 mutations. *Blood Cancer Journal*, **2019**, 9, 20	7	6
219	Genetic Factors in Acute Myeloid Leukemia With Myelodysplasia-Related Changes. *American Journal of Clinical Pathology*, **2020**, 153, 656-663	1.9	6
218	A Test Utilization Approach to the Diagnostic Workup of Isolated Eosinophilia in Otherwise Morphologically Unremarkable Bone Marrow: A Single Institutional Experience. *American Journal of Clinical Pathology*, **2018**, 150, 421-431	1.9	6
217	The Impact of Upfront Autologous Transplant on the Survival of Adult Patients with ALCL and PTCL-NOS According to Their ALK, DUSP22 and TP63 Gene Rearrangement Status - a Joined Nordic Lymphoma Group and Mayo Clinic Analysis. *Blood*, **2017**, 130, 822-822	2.2	6
216	Use of mate-pair sequencing to characterize a complex cryptic BCR/ABL1 rearrangement observed in a newly diagnosed case of chronic myeloid leukemia. *Human Pathology*, **2019**, 89, 109-114	3.7	6
215	Landscape of RAS pathway mutations in patients with myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: a study of 461 molecularly annotated patients. *Leukemia*, **2021**, 35, 644-649	10.7	6
214	Mantle cell lymphoma with a novel t(11;12)(q13;p11.2): a proposed alternative mechanism of CCND1 up-regulation. *Human Pathology*, **2017**, 64, 207-212	3.7	5
213	Combined Tumors in Hematolymphoid Neoplasms: Case Series of Histiocytic and Langerhans Cell Sarcomas Arising From Low-Grade B-Cell Lymphoma. *BMC Clinical Pathology*, **2019**, 12, 2632010X19878410	1.2	5
212	The significance of genetic mutations and their prognostic impact on patients with incidental finding of isolated del(20q) in bone marrow without morphologic evidence of a myeloid neoplasm. *Blood Cancer Journal*, **2020**, 10, 7	7	5

211	FGFR1 rearranged hematological neoplasms - molecularly defined and clinically heterogeneous. *Leukemia and Lymphoma*, **2018**, 59, 1520-1522	1.9	5
210	Nonhepatosplenic extramedullary manifestations of chronic myelomonocytic leukemia: clinical, molecular and prognostic correlates. *Leukemia and Lymphoma*, **2018**, 59, 2998-3001	1.9	5
209	Is It Time for a New Gold Standard? FISH vs Cytogenetics in AML Diagnosis. *American Journal of Clinical Pathology*, **2016**, 145, 430-2	1.9	5
208	A leukemic presentation of a "triple-hit" lymphoma. *Blood*, **2014**, 123, 1126	2.2	5
207	Development of an NPM1/MLF1 D-FISH probe set for the detection of t(3;5)(q25;q35) identified in patients with acute myeloid leukemia. *Journal of Molecular Diagnostics*, **2014**, 16, 527-532	5.1	5
206	Marked elevation of serum lactate dehydrogenase in primary myelofibrosis: clinical and prognostic correlates. *Blood Cancer Journal*, **2017**, 7, 657	7	5
205	Peripheral blood cytogenetic studies in myelofibrosis: overall yield and comparison with bone marrow cytogenetic studies. *Leukemia Research*, **2008**, 32, 1597-600	2.7	5
204	Mutation-Enhanced International Prognostic Systems for Essential Thrombocythemia (MIPSS-ET) and Polycythemia Vera (MIPSS-PV). *Blood*, **2018**, 132, 578-578	2.2	5
203	Tipifarnib As Maintenance Therapy in Acute Myeloid Leukemia (AML) Improves Survival in a Subgroup of Patients with High Risk Disease. Results of the Phase III Intergroup Trial E2902. *Blood*, **2015**, 126, 1308-1308	2.2	5
202	SF3B1-mutant CMML defines a predominantly dysplastic CMML subtype with a superior acute leukemia-free survival. *Blood Advances*, **2020**, 4, 5716-5721	7.8	5
201	Rapid assessment of hyperdiploidy in plasma cell disorders using a novel multi-parametric flow cytometry method. *American Journal of Hematology*, **2019**, 94, 424-430	7.1	5
200	The germline JAK2 GGCC (46/1) haplotype and survival among 414 molecularly-annotated patients with primary myelofibrosis. *American Journal of Hematology*, **2019**, 94, 299-305	7.1	5
199	The Prognostic Role of Structural Variants Identified by NGS and FISH in Multiple Myeloma. *Clinical Cancer Research*, **2021**,	12.9	5
198	CD36-positive B-lymphoblasts Predict Poor Outcome in Children With B-lymphoblastic Leukemia. *Pediatric and Developmental Pathology*, **2017**, 20, 224-231	2.2	4
197	A simple additive staging system for newly diagnosed multiple myeloma.. *Blood Cancer Journal*, **2022**, 12, 21	7	4
196	Decreased Levels of Total or HDL Cholesterol in Primary Myelofibrosis Are Associated with Shortened Survival: DIPSS-Plus Independent Prognostic Value.. *Blood*, **2012**, 120, 2851-2851	2.2	4
195	Momelotinib Therapy in Myelofibrosis: 6-Years Follow-up Data on Safety, Efficacy and the Impact of Mutations on Overall and Relapse-Free Survival. *Blood*, **2016**, 128, 1123-1123	2.2	4
194	Characterization of a cryptic fusion by mate-pair sequencing in a case of acute promyelocytic leukemia with a normal karyotype and negative FISH studies. *Leukemia and Lymphoma*, **2020**, 61, 975-978	1.9	4

193	Deletion 5q is frequent in myelodysplastic syndrome (MDS) patients diagnosed with interstitial lung diseases (ILD): Mayo Clinic experience. *Leukemia Research*, **2016**, 50, 112-115	2.7	4
192	Extramedullary acute myeloid leukemia presenting in young adults demonstrates sensitivity to high-dose anthracycline: a subset analysis from ECOG-ACRIN 1900. *Haematologica*, **2019**, 104, e147-e150	6.6	4
191	Constitutional chromosome rearrangements that mimic the 2017 world health organization "acute myeloid leukemia with recurrent genetic abnormalities": A study of three cases and review of the literature. *Cancer Genetics*, **2019**, 230, 37-46	2.3	4
190	Cryptic and atypical KMT2A-USP2 and KMT2A-USP8 rearrangements identified by mate pair sequencing in infant and childhood leukemia. *Genes Chromosomes and Cancer*, **2020**, 59, 422-427	5	4
189	Detection of cryptic CCND1 rearrangements in mantle cell lymphoma by next generation sequencing. *Annals of Diagnostic Pathology*, **2020**, 46, 151533	2.2	3
188	Myeloid neoplasm with eosinophilia associated with isolated extramedullary FIP1L1/PDGFRA rearrangement. *Cancer Genetics*, **2018**, 220, 13-18	2.3	3
187	Characterization of a rarely reported STAT5B/RARA gene fusion in a young adult with newly diagnosed acute promyelocytic leukemia with resistance to ATRA therapy. *Cancer Genetics*, **2019**, 237, 51-54	2.3	3
186	Myeloid Sarcoma With CBFB-MYH11 Fusion (inv(16) or t(16;16)) Prevails in the Abdomen. *American Journal of Clinical Pathology*, **2020**, 153, 333-341	1.9	3
185	Effect of the Number of Prognostically Relevant Mutated Genes on Survival and Leukemia Progression in Primary Myelofibrosis. *Blood*, **2013**, 122, 104-104	2.2	3
184	Myeloid Sarcoma: The Mayo Clinic Experience of Ninety Six Case Series. *Blood*, **2016**, 128, 2798-2798	2.2	3
183	Identification of t(1;19)(q12;p13) and ploidy changes in an ependymosarcoma: a cytogenetic evaluation **2012**, 31, 142-5		3
182	Striking Association of Lymphoid Enhancing Factor (LEF1) Overexpression and DUSP22 Rearrangements in Anaplastic Large Cell Lymphoma. *American Journal of Surgical Pathology*, **2021**, 45, 550-557	6.7	3
181	Indolent Mantle Cell Lymphoma: A Distinct Subgroup Characterized by Leukemic Phase Disease without Lymphadenopathy.. *Blood*, **2009**, 114, 3937-3937	2.2	3
180	Molecular and phenotypic characterization of an early T-cell precursor acute lymphoblastic lymphoma harboring PICALM-MLLT10 fusion with aberrant expression of B-cell antigens. *Cancer Genetics*, **2020**, 240, 40-44	2.3	3
179	Acute myeloid leukemia after age 70 years: A retrospective comparison of survival following treatment with intensive versus HMA venetoclax chemotherapy. *American Journal of Hematology*, **2021**, 96, E108-E111	7.1	3
178	Clinical, molecular, and prognostic comparisons between CCUS and lower-risk MDS: a study of 187 molecularly annotated patients. *Blood Advances*, **2021**, 5, 2272-2278	7.8	3
177	20+ Years and alive with primary myelofibrosis: Phenotypic signature of very long-lived patients. *American Journal of Hematology*, **2019**, 94, 286-290	7.1	3
176	Decreased survival and increased rate of fibrotic progression in essential thrombocythemia chronicled after the FDA approval date of anagrelide. *American Journal of Hematology*, **2019**, 94, 5-9	7.1	3

175	Fluorescence in-situ hybridisation for TP63 rearrangements in T cell lymphomas: single-site experience of 470 patients and implications for clinical testing. *Histopathology*, **2020**, 76, 481-485	7.3	3
174	Myeloid malignancies with 5q and 7q deletions are associated with extreme genomic complexity, biallelic TP53 variants, and very poor prognosis. *Blood Cancer Journal*, **2021**, 11, 18	7	3
173	Serum erythropoietin levels in essential thrombocythemia: phenotypic and prognostic correlates. *Blood Cancer Journal*, **2018**, 8, 118	7	3
172	Identification of adult Philadelphia-like acute lymphoblastic leukemia using a FISH-based algorithm distinguishes prognostic groups and outcomes. *Blood Cancer Journal*, **2021**, 11, 156	7	3
171	The 2016 revised World Health Organization definition of 'myelodysplastic syndrome with isolated del(5q)'; prognostic implications of single versus double cytogenetic abnormalities. *British Journal of Haematology*, **2017**, 178, 57-60	4.5	2
170	Phenotypic correlates and prognostic outcomes of TET2 mutations in myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: A comprehensive study of 504 adult patients. *American Journal of Hematology*, **2020**, 95, E86-E89	7.1	2
169	Characterizing false-positive fluorescence in situ hybridization results by mate-pair sequencing in a patient with chronic myeloid leukemia and progression to myeloid blast crisis. *Cancer Genetics*, **2020**, 243, 48-51	2.3	2
168	Whole Genome Mate-pair Sequencing of Plasma Cell Neoplasm as a Novel Diagnostic Strategy: A Case of Unrecognized t(2;11) Structural Variation. *Clinical Lymphoma, Myeloma and Leukemia*, **2019**, 19, 598-602	2	2
167	Sustained remission in a patient with myelodysplastic syndrome and a complex karyotype after erythropoiesis-stimulating therapy followed by colonic T-cell lymphoblastic lymphoma. *Leukemia and Lymphoma*, **2013**, 54, 1534-7	1.9	2
166	When are apparently non-clonal abnormalities in bone marrow chromosome studies actually clonal?. *Cancer Genetics*, **2012**, 205, 405-9	2.3	2
165	Philadelphia chromosome mosaicism at diagnosis in chronic myeloid leukemia: clinical correlates and effect on imatinib mesylate treatment outcome. *Leukemia and Lymphoma*, **2007**, 48, 2137-40	1.9	2
164	Concomitant myelodysplastic syndrome and chronic myeloid leukaemia: treatment outcomes with imatinib mesylate. *British Journal of Haematology*, **2003**, 123, 366-7	4.5	2
163	PRE: a novel element with the hallmarks of a retrotransposon derived from an unknown structural RNA. *Nucleic Acids Research*, **1992**, 20, 5233	20.1	2
162	Lymphocytopenia predicts shortened survival in myelodysplastic syndrome with ring sideroblasts (MDS-RS) but not in MDS/MPN-RS-T.. *American Journal of Hematology*, **2021**,	7.1	2
161	ASXL1 and SETBP1 Mutations and Their Prognostic Contribution In Chronic Myelomonocytic Leukemia: An International Study Of 431 Patients. *Blood*, **2013**, 122, 1510-1510	2.2	2
160	Impact Of FISH Abnormalities On Response To Lenalidomide In Patients With Multiple Myeloma. *Blood*, **2013**, 122, 3210-3210	2.2	2
159	ASXL1 and CBL Mutations Are Independently Predictive of Inferior Survival in Advanced Systemic Mastocytosis. *Blood*, **2015**, 126, 828-828	2.2	2
158	Prognostic Impact of Morphology, MYC Gene Partner and BCL2/BCL6 Translocation Status in "High Grade B-Cell Lymphomas with MYC and BCL2 and/or BCL6 Rearrangements". *Blood*, **2016**, 128, 1750-1750	2.2	2

157	Marked Elevation of Serum Lactate Dehydrogenase (LDH) in Primary Myelofibrosis: Clinical and Prognostic Correlates. *Blood*, **2016**, 128, 3113-3113	2.2	2
156	Prefibrotic Versus Overtly Fibrotic Primary Myelofibrosis: Clinical, Cytogenetic, Molecular and Prognostic Comparisons. *Blood*, **2016**, 128, 4247-4247	2.2	2
155	Monocytosis Is a Powerful and Independent Predictor of Shortened Overall and Leukemia-Free Survival in Primary Myelofibrosis. *Blood*, **2016**, 128, 4249-4249	2.2	2
154	Conventional Cytogenetic Analysis of Hematologic Neoplasms: A 20-Year Review of Proficiency Test Results From the College of American Pathologists/American College of Medical Genetics and Genomics Cytogenetics Committee. *Archives of Pathology and Laboratory Medicine*, **2021**, 145, 176-190	5	2
153	Discovery of 6 Novel Translocations Involving the Imatinib Responsive Genes PDGFRB and PDGFRB from Screening 29,047 Abnormal Bone Marrow Specimens.. *Blood*, **2004**, 104, 2902-2902	2.2	2
152	Clinical utility of fluorescence in situ hybridization-based diagnosis of BCR-ABL1 like (Philadelphia chromosome like) B-acute lymphoblastic leukemia. *American Journal of Hematology*, **2020**, 95, E68-E72	7.1	2
151	Assessment of isochromosome 12p and 12p abnormalities in germ cell tumors using fluorescence in situ hybridization, single-nucleotide polymorphism arrays, and next-generation sequencing/mate-pair sequencing. *Human Pathology*, **2021**, 112, 20-34	3.7	2
150	Determinants of long-term outcome in type 1 calreticulin-mutated myelofibrosis. *Leukemia*, **2019**, 33, 780-785	10.7	2
149	Clinical correlates and prognostic impact of clonal hematopoiesis in multiple myeloma patients receiving post-autologous stem cell transplantation lenalidomide maintenance therapy. *American Journal of Hematology*, **2021**, 96, E157-E162	7.1	2
148	Immunophenotypic and laboratory features of t(11;14)(q13;q32)-positive plasma cell neoplasms. *Leukemia and Lymphoma*, **2018**, 59, 1913-1919	1.9	2
147	A novel predictive model of outcome in acute myeloid leukemia without favorable karyotype based on treatment strategy, karyotype and FLT3-ITD mutational status. *American Journal of Hematology*, **2018**, 93, E401-E404	7.1	2
146	Practice-relevant demarcation of systemic mastocytosis associated with another hematologic neoplasm. *American Journal of Hematology*, **2018**, 93, E383-E386	7.1	2
145	Cytogenetic clonal evolution in myeloproliferative neoplasms: contexts and prognostic impact among 648 patients with serial bone marrow biopsies. *Leukemia*, **2019**, 33, 2522-2553	10.7	1
144	ADDENDUM: Section E9 of the American College of Medical Genetics Technical Standards and Guidelines: Fluorescence in situ hybridization. *Genetics in Medicine*, **2019**, 21, 2405	8.1	1
143	A near-haploid clone harboring a BCR/ABL1 gene fusion in an adult patient with newly diagnosed B-lymphoblastic leukemia. *Genes Chromosomes and Cancer*, **2019**, 58, 665-668	5	1
142	The impact of sex on disease phenotype and prognostic thresholds of anemia in myelodysplastic syndromes. *American Journal of Hematology*, **2018**, 93, E164-E167	7.1	1
141	Revisiting the need for bone marrow examination in chronic myeloid leukemia. *American Journal of Hematology*, **2018**, 93, 5-7	7.1	1
140	Differences in the distribution of cytogenetic subtypes between multiple myeloma patients with and without a family history of monoclonal gammopathy and multiple myeloma. *European Journal of Haematology*, **2013**, 91, 193-5	3.8	1

139	Myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T): Mayo-Moffitt collaborative study of 158 patients.. *Blood Cancer Journal*, **2022**, 12, 26	7	1
138	-mutant myelodysplastic syndrome/myeloproliferative neoplasms: a unique molecular and prognostic entity.. *Haematologica*, **2022**,	6.6	1
137	3,023 Mayo Clinic Patients with Myeloproliferative Neoplasms: Risk-Stratified Comparison of Survival and Outcomes Data Among Disease Subgroups. *Blood*, **2018**, 132, 3035-3035	2.2	1
136	Mutations and Thrombosis in Essential Thrombocythemia and Polycythemia Vera: Mayo-Careggi Alliance Study. *Blood*, **2018**, 132, 3040-3040	2.2	1
135	14q32 Abnormalities and 13q Deletions Are Common in Primary Systemic Amyloidosis Using Cytoplasmic Immunoglobulin Fluorescence In Situ Hybridization (cIg-FISH).. *Blood*, **2007**, 110, 2477-2477	2.2	1
134	R115777(tipifarnib) Improves Early Survival when Used As Maintenance Therapy for Elderly or Relapsed/Refractory Patients with Acute Myelogenous Leukemia in Remission. *Blood*, **2012**, 120, 676-676	2.2	1
133	Clonal Evolution As Determined By Sequential Bone Marrow Karyotype Analysis During JAK Inhibitor Therapy For Myelofibrosis: Impact On Treatment Response and Overall and Leukemia-Free Survival. *Blood*, **2013**, 122, 2821-2821	2.2	1
132	Driver Mutations and Prognosis in 502 Patients with Essential Thrombocythemia. *Blood*, **2015**, 126, 1599-1599	2.2	1
131	Driver Mutations and Prognosis in 1118 Patients with Primary Myelofibrosis. *Blood*, **2015**, 126, 2801-2801	2.2	1
130	A 27-Gene NGS Panel in Primary Myelofibrosis Identifies ASXL1, CBL, RUNX1 and SRSF2 Mutations As Being Unfavorable and Absence of Any Non-Driver Mutation As Being Favorable to Survival. *Blood*, **2015**, 126, 350-350	2.2	1
129	Treatment and Clinical Outcomes of High Grade B-Cell Lymphomas with MYC and BCL2 and/or BCL6 Rearrangements (Double Hit/Triple Hit Lymphomas). *Blood*, **2016**, 128, 155-155	2.2	1
128	Abnormal Karyotype and Prognosis in Polycythemia Vera: A Single Center Experience in 239 Informative Cases. *Blood*, **2016**, 128, 3115-3115	2.2	1
127	U2AF1 Mutation Variants and Their Phenotypic and Prognostic Relevance in Primary Myelofibrosis. *Blood*, **2016**, 128, 4248-4248	2.2	1
126	Number and Type of TET2 Mutations in Chronic Myelomonocytic Leukemia: Clinical and Prognostic Correlates. *Blood*, **2016**, 128, 4343-4343	2.2	1
125	Risk Factors for Arterial Versus Venous Thrombosis in Polycythemia Vera: Single Center Experience in 587 Patients. *Blood*, **2016**, 128, 948-948	2.2	1
124	Histologic and Immunohistochemical Study of Bone Marrow Monocytic Nodules in 21 Cases With Myelodysplasia. *American Journal of Clinical Pathology*, **2003**, 120, 874-881	1.9	1
123	Low Level Amplification (Duplication) of 1q21 in Myeloma and Prognosis; the Role of CKS1B.. *Blood*, **2005**, 106, 624-624	2.2	1
122	Anaplastic Angiocentric Glioma: A Report of Two Cases. *FASEB Journal*, **2008**, 22, 706.4	0.9	1

121	High Level MYC Amplification in Aggressive B-Cell Lymphomas: Is It a Marker of Aggressive Disease?. *Blood*, **2018**, 132, 1693-1693	2.2	1
120	A Novel Approach to Risk Stratification in Multiple Myeloma Using ISS Stage and FISH. *Blood*, **2019**, 134, 1800-1800	2.2	1
119	Novel Mutations in NOTCH and Altered Wnt/β-Catenin Pathway Indicate a Role of Embryonic Signals in the Pathogenesis of T-Cell Prolymphocytic Leukemia. *Blood*, **2016**, 128, 4103-4103	2.2	1
118	Secondary acquisition of BCR-ABL1 fusion in de novo GATA2-MECOM positive acute myeloid leukemia with subsequent emergence of a rare KMT2A-ASXL2 fusion. *Cancer Genetics*, **2020**, 241, 67-71	2.3	1
117	Mayo Clinic experience with 1123 adults with acute myeloid leukemia. *Blood Cancer Journal*, **2021**, 11, 46	7	1
116	CSF3R T618I mutant chronic myelomonocytic leukemia (CMML) defines a proliferative CMML subtype enriched in ASXL1 mutations with adverse outcomes. *Blood Cancer Journal*, **2021**, 11, 54	7	1
115	Genomic stratification of myelodysplastic/myeloproliferative neoplasms, unclassifiable: Sorting through the unsorted. *Leukemia*, **2021**, 35, 3329-3333	10.7	1
114	Increased complexity of t(11;14) rearrangements in plasma cell neoplasms compared with mantle cell lymphoma. *Genes Chromosomes and Cancer*, **2021**, 60, 678-686	5	1
113	Identification of a novel KMT2A/GIMAP8 gene fusion in a pediatric patient with acute undifferentiated leukemia. *Genes Chromosomes and Cancer*, **2021**, 60, 108-111	5	1
112	Biphenotypic Acute Leukemia versus Myeloid Antigen-Positive ALL: Clinical Relevance of WHO Criteria for Mixed Phenotype Acute Leukemia. *Case Reports in Hematology*, **2018**, 2018, 7456378	0.7	1
111	De novo isolated myeloid sarcoma: comparative analysis of survival in 19 consecutive cases. *British Journal of Haematology*, **2021**, 195, 413-416	4.5	1
110	Spectrum of hematological malignancies, clonal evolution and outcomes in 144 Mayo Clinic patients with germline predisposition syndromes. *American Journal of Hematology*, **2021**, 96, 1450-1460	7.1	1
109	Cytogenetic abnormalities in essential thrombocythemia: Clinical and molecular correlates and prognostic relevance in 809 informative cases.. *Blood Cancer Journal*, **2022**, 12, 44	7	1
108	Characterization of a cryptic KMT2A/AFF1 gene fusion by mate-pair sequencing (MPseq) in a young adult with newly diagnosed B-lymphoblastic leukemia. *Journal of Hematopathology*, **2019**, 12, 99-104	0.4	0
107	Anaplastic large-cell lymphoma (ALK-negative)-related heart failure and recurrence after heart transplantation. *Journal of Heart and Lung Transplantation*, **2020**, 39, 1156-1158	5.8	0
106	Normal karyotype in myelofibrosis: is prognostic integrity affected by the number of metaphases analyzed?. *Blood Cancer Journal*, **2018**, 8, 8	7	0
105	20+ Years and Alive with Primary Myelofibrosis: Phenotypic Signature of Very Long-Lived Patients. *Blood*, **2018**, 132, 4301-4301	2.2	0
104	SF3B1 Mutations Are Prevalent in Myelodysplastic Syndromes with Ring Sideroblasts but Do Not Hold Independent Prognostic Value. *Blood*, **2011**, 118, 460-460	2.2	0

103	MYC break-apart FISH probe set reveals frequent unbalanced patterns of uncertain significance when evaluating aggressive B-cell lymphoma. *Blood Cancer Journal*, **2021**, 11, 184	7	0
102	Characterization of Atypical t(11;14) CCND1/IGH Translocations in Multiple Myeloma. *Blood*, **2021**, 138, 3771-3771	2.2	0
101	Acute Myeloid Leukemia in the Context of Previous History of Cancer with or without Exposure to Chemotherapy or Radiotherapy. *Blood*, **2021**, 138, 3368-3368	2.2	0
100	"Proliferative" Versus "Dysplastic" Chronic Myelomonocytic Leukemia: Molecular and Prognostic Correlates. *Blood*, **2016**, 128, 1987-1987	2.2	0
99	Unique Clinical Epidemiologic Risk Factors Are Associated with Distinct Methylation Subgroups in Newly-Diagnosed Acute Myeloid Leukemia (AML). *Blood*, **2016**, 128, 1719-1719	2.2	0
98	Subnormal Lymphocyte Count Predicts Inferior Survival in Myelodysplastic Syndromes: A Single Center Experience in 889 Patients. *Blood*, **2016**, 128, 5534-5534	2.2	0
97	Siblings with ETV6/RUNX1-positive B-lymphoblastic leukemia: A single site experience and review of the literature. *Annals of Diagnostic Pathology*, **2020**, 48, 151588	2.2	0
96	Genetic predictors of response to specific drugs in primary myelofibrosis. *Blood Cancer Journal*, **2018**, 8, 120	7	0
95	Clinical utility of next generation sequencing to detect IGH/IL3 rearrangements [t(5;14)(q31.1;q32.1)] in B-lymphoblastic leukemia/lymphoma. *Annals of Diagnostic Pathology*, **2021**, 53, 151761	2.2	0
94	A rare case of atypical chronic myeloid leukemia associated with t(8;22)(p11.2;q11.2)/ BCR-FGFR1 rearrangement: A case report and literature review. *Cancer Genetics*, **2021**, 258-259, 69-73	2.3	0
93	Clonal compositions involving epigenetic regulator and splicing mutations in CHIP, CCUS, MDS, and CMML.. *Leukemia Research*, **2022**, 106818	2.7	0
92	Identification of EWSR1 rearrangements in patients with immature hematopoietic neoplasms: A case series and review of literature.. *Annals of Diagnostic Pathology*, **2022**, 58, 151942	2.2	0
91	Apparent coexistence of and fusions due to a nonproductive rearrangement in B-ALL.. *Leukemia and Lymphoma*, **2022**, 1-4	1.9	0
90	RNAseq identification of FISH-cryptic BCL6::TP63 rearrangement in ALK-negative anaplastic large cell lymphoma.. *Histopathology*, **2022**,	7.3	0
89	Characterization of a t(1;2)(p36;p21) involving the PRDM16 gene region by mate-pair sequencing (MPseq) in a patient with newly diagnosed acute myeloid leukemia with myelodysplasia-related changes. *Journal of Hematopathology*, **2019**, 12, 85-90	0.4	
88	Test Samples and Laboratory Protocols **2006**, 292-339		
87	The Prognostic Significance of Acquired 1q22 Gain in Multiple Myeloma. *Blood*, **2020**, 136, 9-10	2.2	
86	Heterogeneity of MYC Abnormalities in Multiple Myeloma. *Blood*, **2020**, 136, 2-3	2.2	

85	Clinical Value of Next Generation Sequencing in the Detection of Recurring Structural Rearrangements and Copy Number Abnormalities in Acute Myeloid Leukemia. *Blood*, **2020**, 136, 21-22	2.2
84	Striking Association of Lymphoid Enhancing Factor (LEF1) Overexpression and DUSP22 rearrangements in Anaplastic Large Cell Lymphoma. *Blood*, **2020**, 136, 22-23	2.2
83	Utilizing next-generation sequencing to characterize a case of acute myeloid leukemia with t(4;12)(q12;p13) in the absence of ETV6/CHIC2 and ETV6/PDGFRA gene fusions. *Cancer Genetics*, **2021**, 260-261, 1-5	2.3
82	Anthracycline Choices for Induction Chemotherapy Among 797 Consecutive Adult Patients with Acute Myeloid Leukemia: Daunorubicin-60 Vs Idarubicin-12 Vs Daunorubicin-90. *Blood*, **2021**, 138, 1267-1267	2.2
81	Cytogenetics in Essential Thrombocythemia: Phenotype and Molecular Correlates and Prognostic Relevance in 818 Informative Cases. *Blood*, **2021**, 138, 3629-3629	2.2
80	Cryptic t(6;11) KMT2A rearrangement in a pediatric acute myeloid leukemia patient detected by next-generation sequencing and dual-fusion FISH analysis. *Pediatric Blood and Cancer*, **2021**, e29428	3
79	False-Negative Centromere 15 Probe Results in Association with African Ancestry in Plasma Cell Dyscrasias. *Blood*, **2021**, 138, 4101-4101	2.2
78	Bone Marrow Histologic and Cytogenetic Changes during Leukemic Transformation of Myelofibrosis with Myeloid Metaplasia.. *Blood*, **2004**, 104, 4750-4750	2.2
77	Low Incidence of FIP1L1-PDGFRA in Eosinophilic Patients and Long-Term Experience with Imatinib Therapy.. *Blood*, **2005**, 106, 2590-2590	2.2
76	Additional Cytogenetic Abnormalities and/or Philadelphia Chromosome Metaphase Mosaicism Might Adversely Influence Survival and Imatinib Response in Chronic Myeloid Leukemia.. *Blood*, **2006**, 108, 4783-4783	2.2
75	Idiopathic Eosinophilia with an Occult T-Cell Clone: Prevalence, FIP1L1-PDGFRA Status, and Clinical Course.. *Blood*, **2006**, 108, 2701-2701	2.2
74	Natural History, Genetic Aberrations and Survival Distinguish Primary Plasma Cell Leukemia from Multiple Myeloma with Leukemic Transformation.. *Blood*, **2006**, 108, 3587-3587	2.2
73	Peripheral Blood Cytogenetic Studies in Hematological Neoplasms: Predictors of Obtaining Metaphases for Analysis.. *Blood*, **2007**, 110, 3504-3504	2.2
72	Impact of Acquired Del(17p) in Patients with Multiple Myeloma. *Blood*, **2018**, 132, 4449-4449	2.2
71	Predictors of Spleen and Anemia Response to Specific Drugs in Primary Myelofibrosis. *Blood*, **2018**, 132, 4300-4300	2.2
70	Association of Clinical Epidemiologic Exposures and Overall Survival with Genome-Wide DNA Methylation Profiles in Acute Myeloid Leukemia: Analysis of the Mayo Clinic AML Epidemiology Cohort. *Blood*, **2018**, 132, 3987-3987	2.2
69	Serum Erythropoietin Levels in Essential Thrombocythemia: Phenotypic and Prognostic Correlates. *Blood*, **2018**, 132, 3034-3034	2.2
68	The Germline JAK2 GGCC (46/1) Haplotype and Survival Among 414 Molecularly-Annotated Patients with Primary Myelofibrosis. *Blood*, **2018**, 132, 1761-1761	2.2

67	Decreased Survival and Increased Rate of Fibrotic Progression in Essential Thrombocythemia Chronicled after the FDA Approval Date of Anagrelide. *Blood*, **2018**, 132, 4287-4287	2.2
66	Clinical and Molecular Models of Prognostication in Mastocytosis: Analysis Based on 580 Consecutive Cases. *Blood*, **2018**, 132, 582-582	2.2
65	Determinants of Long-Term Outcome in Type 1/like Calreticulin-Mutated Myelofibrosis. *Blood*, **2018**, 132, 1767-1767	2.2
64	Cytogenetic Abnormalities in Systemic Mastocytosis: Who Subcategory-Specific Incidence and Prognostic Impact Among 348 Informative Cases. *Blood*, **2018**, 132, 3050-3050	2.2
63	Myeloproliferative Neoplasms in Young Patients: The Mayo Clinic Experience with 361 Cases Age 40 Years or Younger. *Blood*, **2018**, 132, 3033-3033	2.2
62	Cytogenetic Clonal Evolution in Myeloproliferative Neoplasms: Contexts and Prognostic Impact Among 650 Patients with Serial Bone Marrow Biopsies. *Blood*, **2018**, 132, 4291-4291	2.2
61	Frequency of Acquired Genetic Mutations and Their Prognostic Impact on Patients with Incidental Finding of Isolated 20q- in Bone Marrow without Morphologic Evidence of a Myeloid Neoplasm. *Blood*, **2018**, 132, 4382-4382	2.2
60	MPL-Mutated Essential Thrombocythemia: A Morphologic Reappraisal. *Blood*, **2018**, 132, 3036-3036	2.2
59	Clinical Correlates, Prognostic Impact and Survival Outcomes in Chronic Myelomonocytic Leukemia Patients with Myeloproliferative Neoplasm Associated-Driver Mutations. *Blood*, **2018**, 132, 3100-3100	2.2
58	Efficacy of Mitoxantrone-Based Salvage Therapies in Relapsed or Refractory Acute Myeloid Leukemia in the Mayo Clinic Cancer Center: Analysis of Survival after CLAG-M Vs. MEC. *Blood*, **2018**, 132, 2678-2678	2.2
57	1,123 Consecutive Adults with Non-APL Acute Myeloid Leukemia: The Mayo Clinic Experience. *Blood*, **2018**, 132, 2689-2689	2.2
56	Risk Factors for Leukemic Transformation Among 1,306 Patients with Primary Myelofibrosis: Mutations Predict Early Events. *Blood*, **2018**, 132, 3044-3044	2.2
55	A Prospective Evaluation of Vitamin B1 (thiamine) Level in Myeloproliferative Neoplasms: Clinical Correlations and Impact of JAK2 Inhibitor Therapy. *Blood*, **2018**, 132, 1771-1771	2.2
54	Metaphase Cytogenetics for Risk Stratification in Newly Diagnosed Multiple Myeloma. *Blood*, **2019**, 134, 4396-4396	2.2
53	Recurrent Chromosomal Abnormalities in Tumoral Lesions of Small Lymphocytic Lymphoma/Chronic Lymphocytic Leukemia: A Large-Scale Fluorescent in-Situ Hybridization Study on Tissue Biopsy Sections. *Blood*, **2019**, 134, 4282-4282	2.2
52	Differentiating between Hyperdiploidy and Pseudo-Hyperdiploidy in B-Lymphoblastic Leukemia Utilizing Low-Coverage Mate-Pair Sequencing. *Blood*, **2019**, 134, 5212-5212	2.2
51	Vascular Events and Risk Factors for Thrombosis in Refractory Anemia with Ring Sideroblasts and Thrombocytosis (RARS-T). *Blood*, **2015**, 126, 4067-4067	2.2
50	Momelotinib Therapy for Myelofibrosis: Impact on Long-Term Survival and Genotype Correlations. *Blood*, **2015**, 126, 4062-4062	2.2

49	Molecular Correlates of Anemia in Primary Myelofibrosis. *Blood*, **2015**, 126, 4068-4068	2.2
48	Survival Trends in Primary Myelodysplastic Syndromes: A Comparative Analysis of 1000 Patients By Year of Diagnosis and Treatment. *Blood*, **2015**, 126, 2875-2875	2.2
47	Prognostic Interaction Between ASXL1 and TET2 Mutations in Chronic Myelomonocytic Leukemia. *Blood*, **2015**, 126, 2864-2864	2.2
46	Clinical Outcome of Therapy-Related Acute Myeloid Leukemia Is Strongly Related to Cytogenetic Analysis. *Blood*, **2015**, 126, 1401-1401	2.2
45	Survival Trends in Essential Thrombocythemia in the Face of Changing Treatment Practices. *Blood*, **2015**, 126, 2805-2805	2.2
44	Occurrence and Prognostic Significance of Cytogenetic Evolution in Patients with Multiple Myeloma. *Blood*, **2015**, 126, 4176-4176	2.2
43	ASXL1 Mutations in Myelodysplastic Syndromes with 1% or More Ring Sideroblasts: Prevalence, Clinical Correlates and Prognostic Relevance. *Blood*, **2015**, 126, 2882-2882	2.2
42	Prognostic Impact of Bone Marrow Fibrosis in Polycythemia Vera: Validation of the IWG-MRT Study and Additional Observations. *Blood*, **2016**, 128, 3129-3129	2.2
41	Prognostic Relevance of Monocytopenia and Lymphocyte-to-Monocyte Ratio in Primary Myelodysplastic Syndromes. *Blood*, **2016**, 128, 1996-1996	2.2
40	Prognostic Implications of Multiple Cytogenetic High-Risk Abnormalities in Patients with Newly Diagnosed Multiple Myeloma. *Blood*, **2016**, 128, 5615-5615	2.2
39	Monocytosis in Polycythemia Vera: Clinical and Molecular Correlates. *Blood*, **2016**, 128, 4259-4259	2.2
38	Utilization of Mate-Pair Sequencing to Characterize Complex and Novel TCF3 Translocations. *Blood*, **2016**, 128, 4086-4086	2.2
37	Gene Expression Profiling Identifies Distinct Signatures for Dysplastic and Proliferative Chronic Myelomonocytic Leukemia. *Blood*, **2016**, 128, 110-110	2.2
36	Fluorescence in-Situ Hybridization (FISH) Analysis in Untreated AL Amyloidosis Has an Independent Prognostic Impact By Abnormality Type and Treatment Category. *Blood*, **2016**, 128, 3269-3269	2.2
35	Next-Generation Sequencing in Myelodysplastic Syndromes: Prognostic Interaction Between Adverse Mutations and IPSS-R. *Blood*, **2016**, 128, 1986-1986	2.2
34	Predicting Poor Overall Survival in Patients with Newly Diagnosed Multiple Myeloma and Standard-Risk Cytogenetics Treated with Novel Agents. *Blood*, **2016**, 128, 3255-3255	2.2
33	DNTM3A Mutations and Prognosis in Chronic Myelomonocytic Leukemia. *Blood*, **2016**, 128, 1988-1988	2.2
32	Evaluation of Revised International Staging System for Transplant-Eligible Multiple Myeloma Patients. *Blood*, **2016**, 128, 3452-3452	2.2

31	The 2016 Revised World Health Organization Classification of 'Myelodysplastic Syndrome with Isolated Del(5q)'; Prognostic Implications of Single Versus Double Cytogenetic Abnormalities. *Blood* , **2016**, 128, 5542-5542	2.2
30	Identification of Serum Lactate Dehydrogenase (LDH) As an Independent Prognostic Biomarker in Polycythemia Vera. *Blood*, **2016**, 128, 3111-3111	2.2
29	Deletion 5q in AML: A Clinicopathological Description of 79 Cases from a Single Institution. *Blood*, **2008**, 112, 2523-2523	2.2
28	Mechanisms of the Formation of Multinuclear Malignant Plasma Cells in the Novel AL/MM Human Cell Lines, ALMC-1 and ALMC-2: Implications for Tumor Cell Growth Control.. *Blood*, **2008**, 112, 1707-1707	2.2
27	Rearrangements of IER3 Represent a Novel and Recurrent Molecular Abnormality in Myelodysplastic Syndromes (MDS). *Blood*, **2008**, 112, 2679-2679	2.2
26	Isolated Trisomy 8 in the Myelodysplastic Syndromes.. *Blood*, **2009**, 114, 2785-2785	2.2
25	Evidence for Cytogenetic and Fluorescence in Situ Hybridization (FISH) Risk Stratification of Newly Diagnosed Multiple Myeloma in the Era of Novel Therapies.. *Blood*, **2009**, 114, 1802-1802	2.2
24	Autologous Hematopoietic Cell Transplantation as Consolidation for Younger Patients with Acute Myeloid Leukemia in First Complete Remission: Follow-up of E1900.. *Blood*, **2009**, 114, 3405-3405	2.2
23	Prognostic Irrelevance of Ring Sideroblast Percentage in World Health Organization Defined Myelodysplastic Syndromes without Excess Blasts,. *Blood*, **2011**, 118, 3803-3803	2.2
22	The Impact of Obesity on the Presentation & Outcome of Adult Acute Myeloid Leukemia (AML) - ECOG Studies E1900 & E3999. *Blood*, **2011**, 118, 2568-2568	2.2
21	Young Adults Presenting with Extramedullary Acute Myeloid Leukemia Have A Unique Sensitivity to High Doses of Anthracyclines: Subset Analysis of ECOG 1900,. *Blood*, **2011**, 118, 3619-3619	2.2
20	Immunoglobulin Free Light Chain Levels Predict Survival in Primary Myelofibrosis and De Novo Myelodysplastic Syndromes. *Blood*, **2011**, 118, 1756-1756	2.2
19	Differential Prognostic Effect of IDH1 Versus IDH2 Mutations in Myelodysplastic Syndromes: A Mayo Clinic Study of 277 Patients. *Blood*, **2011**, 118, 971-971	2.2
18	TP53 mutations and Polymorphisms in Primary Myelofibrosis,. *Blood*, **2011**, 118, 3840-3840	2.2
17	Spliceosome Mutations Involving SRSF2, SF3B1 and U2AF35 in World Health Organization Defined Chronic Myelomonocytic Leukemia; Prevalence, Clinical Correlates and Prognosis. *Blood*, **2012**, 120, 1711-1711	2.2
16	Phenotypic and Prognostic Correlates of Spliceosome Mutations (SRSF2, SF3B1, U2AF35) in Chronic Myelomonocytic Leukemia with □1% Ring Sideroblasts.. *Blood*, **2012**, 120, 2803-2803	2.2
15	Parallel Transcriptional Analysis of Multiple Stem and Progenitor Populations Identifies Novel Commonly Dysregulated and Functionally Relevant Targets in AML. *Blood*, **2012**, 120, 1875-1875	2.2
14	Survival and Prognosis in World Health Organization Defined Chronic Myelomonocytic Leukemia- A Mayo Clinic Series of 227 Patients. *Blood*, **2012**, 120, 3790-3790	2.2

13	Prognostic Interactions Between SRSF2, ASXL1, and IDH Mutations in Primary Myelofibrosis and Determination of Added Value to Cytogenetic Risk Stratification and DIPSS-Plus. *Blood*, **2012**, 120, 430-430	2.2
12	T(8;9)(p22;p24)/PCM1-JAK2 Activates SOCS2 and SOCS3 Via STAT5. *Blood*, **2012**, 120, 1567-1567	2.2
11	The Effect of Number of Metaphases Studied and Abnormal Metaphase Percentage On Cytogenetic Risk Stratification in Primary Myelofibrosis. *Blood*, **2012**, 120, 1742-1742	2.2
10	Normal Karyotype Primary Myelofibrosis (NK-PMF): Clinical and Molecular Prognostication In 690 Patients. *Blood*, **2013**, 122, 1587-1587	2.2
9	U2AF1 mutations In Primary Myelofibrosis Cluster With Normal Karyotype and JAK2V617F and Are Strongly Associated With Anemia and Thrombocytopenia. *Blood*, **2013**, 122, 4060-4060	2.2
8	Cytogenetic Abnormalities Predict Clinical Outcome In Patients Diagnosed With Relapsed Acute Myeloid Leukemia (rAML): Single Center Experience. *Blood*, **2013**, 122, 4955-4955	2.2
7	Monosomal Karyotype Predicts Adverse Prognosis In Patients With Chronic Myelomonocytic Leukemia. *Blood*, **2013**, 122, 1334-1334	2.2
6	Azacitidine With Or Without Entinostat For The Treatment Of Therapy-Related Myeloid Neoplasm: Further Results Of The E1905 North American Leukemia Intergroup Study. *Blood*, **2013**, 122, 2777-2777	2.2
5	Copy Number Abnormalities Of The Interferon Regulatory Factor-4 (IRF4) Gene Are Associated With IRF4/MUM1 Expression In Peripheral T-Cell Lymphomas. *Blood*, **2013**, 122, 3016-3016	2.2
4	Functional evaluation of isocitrate dehydrogenase 1 and 2 variants of unclear significance in chronic myeloid neoplasms. *Leukemia Research*, **2019**, 87, 106264	2.7
3	Calculator-free point-of-care prognostication in myelodysplastic syndromes. *American Journal of Hematology*, **2019**, 94, E99-E101	7.1
2	Lymphoma-like double-hit genetic abnormalities (and) in a case of non-secretory multiple myeloma. *Leukemia and Lymphoma*, **2021**, 62, 243-246	1.9
1	Dual Primary IGH Translocations in Multiple Myeloma: A Novel Finding. *Clinical Lymphoma, Myeloma and Leukemia*, **2021**, 21, e710-e713	2